GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » PB Ratio

Perspective Therapeutics (Perspective Therapeutics) PB Ratio : 5.92 (As of Apr. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-29), Perspective Therapeutics's share price is $1.58. Perspective Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.27. Hence, Perspective Therapeutics's PB Ratio of today is 5.92.

Warning Sign:

Perspective Therapeutics Inc stock PB Ratio (=5.92) is close to 3-year high of 5.92

The historical rank and industry rank for Perspective Therapeutics's PB Ratio or its related term are showing as below:

CATX' s PB Ratio Range Over the Past 10 Years
Min: 0.53   Med: 2.95   Max: 15.34
Current: 5.92

During the past 13 years, Perspective Therapeutics's highest PB Ratio was 15.34. The lowest was 0.53. And the median was 2.95.

CATX's PB Ratio is ranked worse than
83.27% of 795 companies
in the Medical Devices & Instruments industry
Industry Median: 2.19 vs CATX: 5.92

During the past 12 months, Perspective Therapeutics's average Book Value Per Share Growth Rate was -38.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 47.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 37.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 0.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Perspective Therapeutics was 74.80% per year. The lowest was -49.10% per year. And the median was 13.70% per year.

Back to Basics: PB Ratio


Perspective Therapeutics PB Ratio Historical Data

The historical data trend for Perspective Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics PB Ratio Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.60 6.69 1.68 0.72 1.51

Perspective Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 1.50 1.73 0.78 1.51

Competitive Comparison of Perspective Therapeutics's PB Ratio

For the Medical Devices subindustry, Perspective Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's PB Ratio falls into.



Perspective Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Perspective Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.58/0.267
=5.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Perspective Therapeutics  (AMEX:CATX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Perspective Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (Perspective Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354